论文部分内容阅读
目的:比较米力农与左西孟旦治疗难治性心力衰竭的临床效果。方法:抽取2018年3月至2019年1月滨州市中心医院收治的80例难治性心力衰竭患者为研究对象,按照随机数字表法进行分组。对照组40例患者采用米力农治疗,研究组40例患者采用左西孟旦治疗。比较两组治疗效果、心功能和血清N末端B型利钠肽原(NT-proBNP)水平。结果:研究组治疗总有效率(95.00%,38/40)高于对照组(80.00%,32/40),差异有统计学意义(n P<0.05)。治疗7 d后,观察组左室短轴缩短率(LVFS)、左心室射血分数(LVEF)、每搏输出量(SV)分别为(29.51±4.36)%、(39.61±6.21)%、(74.88±14.73)ml,高于对照组的(22.81±5.57)%、(36.81±5.87)%、(68.16±13.25)ml,观察组血清NT-proBNP为(2 545.61±181.63)ng/L,低于对照组的(3 452.94±203.84)ng/L,n P<0.05。n 结论:左西孟旦治疗难治性心力衰竭的效果优于米力农,可有效改善患者的心功能,降低血清NT-proBNP水平。“,”Objective:To compare the effects of milrinone and levosimendan on patients with refractory heart failure.Methods:A total of 80 patients with refractory heart failure treated in Binzhou Central Hospital from March 2018 to January 2019 were grouped according to random number table method. Forty patients in the control group were treated with milrinone, while 40 patients in the study group were treated with levosimendan. The therapeutic effect, cardiac function, and serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) level were compared between the two groups.Results:The total effective rate of the study group (95.00%, 38/40) was significantly higher than that of the control group (80.00%, 32/40), n P<0.05. The left ventricular fractional shortening (LVFS), left ventricular ejection fraction (LVEF), stroke volume (SV) of the study group were (29.51±4.36)%, (39.61±6.21)%, (74.88±14.73)ml, respectively, higher than the (22.81±5.57)%, (36.81±5.87)%, and (68.16±13.25) ml in the control group, after 7 days of treatment (n P<0.05). The serum NT-proBNP of the study group was (2 545.61±181.63)ng/L, significantly lower than the (3 452.94±203.84)ng/L of the control group after 7 days of treatment (n P<0.05).n Conclusions:Levosimendan is more effective than milrinone in the treatment of refractory heart failure, and the former can effectively improve the cardiac function, and reduce the level of serum NT-proBNP.